Provided By GlobeNewswire
Last update: May 14, 2025
Revenue for the First Quarter Ended March 31, 2025 was $13.1 million
Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025
Read more at globenewswire.com2.12
+0.16 (+8.16%)
6.95
-0.31 (-4.27%)
Find more stocks in the Stock Screener